Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment.
Alzheimers Dement (N Y)
; 6(1): e12002, 2020.
Article
in En
| MEDLINE
| ID: mdl-32211507
ABSTRACT
INTRODUCTION:
The safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia using apolipoprotein E (APOE) genotyping is unknown.METHODS:
We randomized 114 individuals with MCI to receive estimates of 3-year risk of conversion to AD dementia informed by APOE genotyping (disclosure arm) or not (non-disclosure arm) in a non-inferiority clinical trial. Primary outcomes were anxiety and depression scores. Secondary outcomes included other psychological measures.RESULTS:
Upper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index and 0.5 on the Geriatric Depression Scale, below non-inferiority margins of 3.3 and 1.0. Moreover, mean scores were lower in the disclosure arm than non-disclosure arm for test-related positive impact (difference -1.9, indicating more positive feelings) and AD concern (difference -0.3).DISCUSSION:
Providing genetic information to individuals with MCI about imminent risk for AD does not increase risks of anxiety or depression and may provide psychological benefits.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Alzheimers Dement (N Y)
Year:
2020
Document type:
Article